Pharmaceutical Last week’s notable news included US cancer drug developer Sesen Bio being battered after it revealed that the US Food and Drug Administration had issued a compete response letter (CRL) relating to its bladder cancer candidate Vicineum. AbbVie announced new clinical trial results on the efficacy of its investigational migraine prevention treatment atogepant. FibroGen and Japanese partner Astellas said they had been granted approval in Europe for their drug Evrenzo (roxadustat) as a treatment for chronic kidney disease, and UK pharma major AstraZeneca released new data on its antibody therapy for COVID-19, AZD7442. 22 August 2021